DFX Intelligence

Data Factory

Private equityFirmcandidate pe · candidatelower middle market

Frazier Life Sciences Management, LP

Private Equity

Palo Alto, CA

Frazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:8ccc549c-df2f-469b-a84a-3e31d0f746f3

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 1:44 AM UTC and rebuilt at most every 15 minutes.

Relationships: 221
Dated events: 5
On other graphs: 4
Observed: Sep 13, 2026 to Sep 16, 2026
31 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Venture Capitalidentity

Frazier Life Sciences Management, LP

Venture manager · cited, shared crd

Independent Sponsorsidentity

Frazier Life Sciences Management, LP

Capital provider to sponsors · cited, shared crd

RIA / Wealth Managementidentity

FRAZIER LIFE SCIENCES MANAGEMENT, LP

Registered adviser · cited, shared crd

Allocatorsidentity

Frazier Life Sciences Management, LP

Manager with allocator commitments · cited, shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 5
PE funds: 3
Vintages: 2022 to 2023
PE GAV, 2024 filing: $640Mgross asset value on Form ADV; never dry powder
Regulatory AUM: $3.6B
Investments: 141
Active investments: 1
Size band: LOWER MIDDLE MARKETderivedproxy: $0.64bn Private Equity Fund GAV on the Form ADV filed 2024-03-30
Stated sectors: life_sciences,technology
Latest ADV filing: Mar 30, 2024
Employees (ADV): 53
Website: frazierls.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV	LPs
Frazier Life Sciences Public Overage Fund, L.P.	2023	Early deployment	Hedge Fund	n/a	$281M	1
Frazier Healthcare Vii-A, L.P.	2022	Unknown	Private Equity Fund	n/a	$16.1M	0
Frazier Life Sciences Public Fund, L.P.	2022	Early deployment	Hedge Fund	n/a	$900M	1
Frazier Healthcare VII, L.P.	2022	Unknown	Private Equity Fund	n/a	$56.6M	0
Frazier Life Sciences X, L.P.	2022	Unknown	Private Equity Fund	n/a	$567M	0

Investments

Company	State	Role	Control	Invested	Exited	Status
Rapt	n/a	unknown	unknown	Jan 1, 2025	n/a	exited
Adverum	n/a	unknown	unknown	Jan 1, 2024	n/a	exited
Reverse merger in	n/a	unknown	unknown	Jan 1, 2024	n/a	unknown
Aviditybiosciences	n/a	unknown	unknown	Jan 1, 2022	n/a	exited
Veronapharma	n/a	unknown	unknown	Jan 1, 2022	n/a	exited
Kalvista	n/a	unknown	unknown	Jan 1, 2021	n/a	exited
in 2020, SPAC Merger in	n/a	unknown	unknown	Jan 1, 2020	n/a	exited
Acquired in	n/a	unknown	unknown	Jan 1, 2019	n/a	unknown
in 2018;	n/a	unknown	unknown	Jan 1, 2018	n/a	exited
NASDAQ: KRYS	n/a	unknown	unknown	Jan 1, 2018	n/a	unknown
in 2014;	n/a	unknown	unknown	Jan 1, 2017	n/a	exited
Zavante Therapeutics	n/a	unknown	unknown	Jan 1, 2016	n/a	exited
in 2021;	n/a	unknown	unknown	Jan 1, 2014	n/a	exited
Merger with Semnur Pharmaceuticals in	n/a	unknown	unknown	Jan 1, 2013	n/a	exited
Alcresta	n/a	unknown	unknown	Jan 1, 2011	n/a	exited
in 2006;	n/a	unknown	unknown	Jan 1, 2006	n/a	exited
in 2002;	n/a	unknown	unknown	Jan 1, 2000	n/a	exited
in 1996;	n/a	unknown	unknown	Jan 1, 1991	n/a	exited
in 1999;	n/a	unknown	unknown	Jan 1, 1991	n/a	exited
35Pharma	n/a	unknown	unknown	n/a	n/a	unknown
Acerta Pharma	n/a	unknown	unknown	n/a	n/a	unknown
Achaogen	n/a	unknown	unknown	n/a	n/a	unknown
Adverum Biotechnologies	n/a	unknown	unknown	n/a	n/a	unknown
AirNexis Therapeutics, Inc.	n/a	unknown	unknown	n/a	n/a	unknown
Akero Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
Alcresta Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
Alentis Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
Alesta Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
Allena Pharmaceuticals	n/a	unknown	unknown	n/a	n/a	unknown
Alnara Pharmaceuticals	n/a	unknown	unknown	n/a	n/a	unknown

LP commitments

Limited partner	Fund	Commitment	Committed	Vintage
New York State Common Retirement Fund	Frazier Life Sciences Public Fund, L.P.	$170M	n/a	2021
New York State Common Retirement Fund	Frazier Life Sciences Public Overage Fund, L.P.	$50.0M	n/a	2022

Relationships

showing 80 of 221

Invested in (16)

→ Sudo Biosciences, Inc.Companyunknown
factDFX's own graph
→ Amicus TherapeuticsCompanyunknown
factThe subject's own site
→ Amunix PharmaceuticalsCompanyunknown
factThe subject's own site
→ Allena PharmaceuticalsCompanyunknown
factThe subject's own site
→ Alpha-9 OncologyCompanyunknown
factThe subject's own site
→ Alentis TherapeuticsCompanyunknown
factThe subject's own site
→ Alcresta TherapeuticsCompanyunknown
factThe subject's own site
→ Akero TherapeuticsCompanyunknown
factThe subject's own site
→ AirNexis Therapeutics, Inc.Companyunknown
factThe subject's own site
→ Adverum BiotechnologiesCompanyunknown
factThe subject's own site
→ AchaogenCompanyunknown
factThe subject's own site
→ Acerta PharmaCompanyunknown
factThe subject's own site
→ 35PharmaCompanyunknown
factThe subject's own site
→ Alesta TherapeuticsCompanyunknown
factThe subject's own site
→ Alnara PharmaceuticalsCompanyunknown
factThe subject's own site
→ Alpine Immune SciencesCompanyunknown
factThe subject's own site

Employs (64)

→ Michael Varney, Ph.D.PersonSenior Advisor
factThe subject's own site
→ James Bristol, Ph.D.PersonSenior Advisor
factThe subject's own site
→ W. Michael Gallatin, Ph.D.PersonSenior Advisor
factThe subject's own site
→ Robert Hershberg, M.D., Ph.D.PersonSenior Advisor
factThe subject's own site
→ Albert Cha, M.D., Ph.D.PersonManaging Partner
factThe subject's own site
→ Jennifer MartinPersonChief Financial Officer and Partner
factThe subject's own site
→ Lin Mu, M.D., MBAPersonVice President
factThe subject's own site
→ Amanda WilsonPersonSenior Tax Manager
factThe subject's own site
→ James BrushPersonGeneral Partner and Portfolio Manager
factThe subject's own site
→ Aditya Kohli, Ph.D.PersonPartner
factThe subject's own site
→ Anna H. Chen, Ph.D.PersonPartner
factThe subject's own site
→ Joe CabralPersonPartner
factThe subject's own site
→ Kevin Li, M.D.PersonPartner
factThe subject's own site
→ Angel Martin, Ph.D.PersonVice President
factThe subject's own site
→ James N. Topper, M.D., Ph.D.PersonManaging Partner
factThe subject's own site
→ Xinghuo Li, Ph.D.PersonSenior Associate
factThe subject's own site
→ Ashley SlackPersonCounsel, Venture Funds
factThe subject's own site
→ Daniel Estes, Ph.D.PersonGeneral Partner
factThe subject's own site
→ Ryan PeerPersonAssociate
factThe subject's own site
→ Sukh BansalPersonAssociate
factThe subject's own site
→ Adam SimpsonPersonExecutive Partner
factThe subject's own site
→ James Li, M.D.PersonVenture Partner
factThe subject's own site
→ Maria Fardis, Ph.D.PersonVenture Partner
factThe subject's own site
→ Stanford Peng, M.D., Ph.D.PersonVenture Partner
factThe subject's own site
→ Christopher Aakre, Ph.D.PersonPrincipal of Company Creation
factThe subject's own site
→ Lauren Mifflin, Ph.D.PersonPrincipal of Company Creation
factThe subject's own site
→ Mansi ShindePersonVice President of Company Creation
factThe subject's own site
→ Zaneta Odrowaz, Ph.D.PersonVice President of Company Creation
factThe subject's own site
→ Gordon EmpeyPersonPartner, COO and General Counsel
factThe subject's own site
→ April PetersenPersonSenior Accountant
factThe subject's own site
and 34 more

Dated events

3 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Sep 10, 2026
Firm news
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibo
The subject's own siteobserved 2 days ago
Occurred
Nov 18, 2021
Adviser first adv filing
Frazier Life Sciences Management, LP first filed Form ADV in the extract (IA)
Form ADVobserved 5 days ago

Show 3 bookkeeping events

Occurred
Mar 31, 2023
Frazier Life Sciences Public Overage Fund, L.P. first reported on Form ADV by Frazier Life Sciences Management, LP (Private Equity Fund), GAV $253,494,462
Occurred
Mar 31, 2022
Frazier Life Sciences Public Fund, L.P. first reported on Form ADV by Frazier Life Sciences Management, LP (Private Equity Fund), GAV $996,410,303
Occurred
Mar 31, 2022
Frazier Life Sciences X, L.P. first reported on Form ADV by Frazier Life Sciences Management, LP (Venture Capital Fund), GAV $642,061,134

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Michael Varney, Ph.D.
Senior Advisor · Revealable: 2 professional profiles (firm website)
James Bristol, Ph.D.
Senior Advisor · Revealable: 2 professional profiles (firm website)
W. Michael Gallatin, Ph.D.
Senior Advisor · Revealable: 2 professional profiles (firm website)
Robert Hershberg, M.D., Ph.D.
Senior Advisor · Revealable: 2 professional profiles (firm website)
Albert Cha, M.D., Ph.D.
Managing Partner · Revealable: 2 professional profiles (firm website)
Jennifer Martin
Chief Financial Officer and Partner · Revealable: 2 professional profiles (firm website)
Lin Mu, M.D., MBA
Vice President · Revealable: 2 professional profiles (firm website)
Amanda Wilson
Senior Tax Manager · Revealable: 2 professional profiles (firm website)
James Brush
General Partner and Portfolio Manager · Revealable: 2 professional profiles (firm website)
Aditya Kohli, Ph.D.
Partner · Revealable: 2 professional profiles (firm website)
Anna H. Chen, Ph.D.
Partner · Revealable: 2 professional profiles (firm website)
Joe Cabral
Partner · Revealable: 2 professional profiles (firm website)
Kevin Li, M.D.
Partner · Revealable: 2 professional profiles (firm website)
Angel Martin, Ph.D.
Vice President · Revealable: 2 professional profiles (firm website)
James N. Topper, M.D., Ph.D.
Managing Partner · Revealable: 1 professional profile (firm website)
Xinghuo Li, Ph.D.
Senior Associate · Revealable: 2 professional profiles (firm website)
Ashley Slack
Counsel, Venture Funds · Revealable: 2 professional profiles (firm website)
Daniel Estes, Ph.D.
General Partner · Revealable: 2 professional profiles (firm website)
Ryan Peer
Associate · Revealable: 2 professional profiles (firm website)
Sukh Bansal
Associate · Revealable: 2 professional profiles (firm website)
Adam Simpson
Executive Partner · Revealable: 2 professional profiles (firm website)
James Li, M.D.
Venture Partner · Revealable: 2 professional profiles (firm website)
Maria Fardis, Ph.D.
Venture Partner · Revealable: 2 professional profiles (firm website)
Stanford Peng, M.D., Ph.D.
Venture Partner · Revealable: 2 professional profiles (firm website)
Christopher Aakre, Ph.D.
Principal of Company Creation · Revealable: 2 professional profiles (firm website)
Lauren Mifflin, Ph.D.
Principal of Company Creation · Revealable: 2 professional profiles (firm website)
Mansi Shinde
Vice President of Company Creation · Revealable: 2 professional profiles (firm website)
Zaneta Odrowaz, Ph.D.
Vice President of Company Creation · Revealable: 2 professional profiles (firm website)
Gordon Empey
Partner, COO and General Counsel · Revealable: 2 professional profiles (firm website)
April Petersen
Senior Accountant · Revealable: 2 professional profiles (firm website)
Dan Ontiveros, J.D.
Chief Compliance Officer · Revealable: 2 professional profiles (firm website)
Ali Jackson
Vice President and Counsel, Public Funds · Revealable: 2 professional profiles (firm website)
Kiah Williams, M.D.
Vice President · Revealable: 2 professional profiles (firm website)
Patrick Heron
Managing Partner · Revealable: 2 professional profiles (firm website)
Duncan Johnson
Controller, Public Fund Accounting · Revealable: 2 professional profiles (firm website)
Chris Wyckoff
Director of Finance · Revealable: 2 professional profiles (firm website)
Helen Kang
Senior Manager, Trade Operations and Compliance · Revealable: 2 professional profiles (firm website)
Nirav Shah, M.D.
Senior Associate · Revealable: 2 professional profiles (firm website)
Holly Aldrich
Executive Assistant · Revealable: 2 professional profiles (firm website)
Jin Ming (DeeDee) Yu
Corporate Accountant · Revealable: 2 professional profiles (firm website)

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:8ccc549c-df2f-469b-a84a-3e31d0f746f3
First observed: Sep 13, 2026
Last observed: Sep 16, 2026 2 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Frazier Life Sciences Management, LP

Private Equity

Palo Alto, CA

Frazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:8ccc549c-df2f-469b-a84a-3e31d0f746f3

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 1:44 AM UTC and rebuilt at most every 15 minutes.